Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX and SBRT in Unresectable Locally Advanced Pancreatic Cancer
NCT03891472Phase 2Completed
- Sponsor
- Medical University of Silesia
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan and fluorouracil in Pancreatic ductal adenocarcinoma (PDAC), sponsored by Medical University of Silesia. Primary endpoint: Improvement of the therapeutic index at 24 months. Started Jan 2017; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracil
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03891472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891472.